Avalo Therapeutics
AVTX
55 hedge funds and large institutions have $127M invested in Avalo Therapeutics in 2020 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
58% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 12
43% more capital invested
Capital invested by funds: $88.5M → $127M (+$38.5M)
28% more funds holding
Funds holding: 43 → 55 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$14.3M |
| 2 |
AC
Armistice Capital
New York
|
+$4.42M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.95M |
| 4 |
SCM
Sio Capital Management
New York
|
+$2.52M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$407K |
| 2 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$64K |
| 3 |
JP Morgan Chase
New York
|
-$50.8K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$48K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$42K |
AVTX Hedge Fund Activity: Q2 2020 in Review
55 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2020, worth a combined $127M — up 43% from $88.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AVTX positions and 4 closed out — a net gain of 12 holders — while 19 added to existing stakes and 12 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Ikarian Capital, cutting an estimated $407K.
- 55 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2020, up from 43 in Q1 2020.
- Funds reported $127M of Avalo Therapeutics stock for Q2 2020, up 43% quarter-over-quarter.
- 16 funds opened new Avalo Therapeutics positions in Q2 2020 and 4 closed out, a net change of +12 holders.
- The largest Avalo Therapeutics buyer in Q2 2020 was Nantahala Capital Management, an estimated $14.3M added.
- The largest Avalo Therapeutics seller in Q2 2020 was Ikarian Capital, an estimated $407K sold.
Based on aggregated 13F filings for Q2 2020.